NCT03855371 2022-11-04
PANDA-T0
Ruijin Hospital
Phase 1 Unknown
Clinical Trials
11 trialsNCT05497310 2022-10-26
Effectiveness and Safety of Therapy Based on Attenuated ATO Plus Low-Dose ATRA in Patients With APL
Hospital Universitario Dr. Jose E. Gonzalez
Phase 1/2 Unknown
NCT05297123 2022-03-28
Treatment of Acute Myeloid Leukemia With Arsenic and All-trans Retinoid Acid
First Affiliated Hospital Xi'an Jiaotong University
Phase 1 Unknown
NCT03751917 2022-01-04
APL0618
Gruppo Italiano Malattie EMatologiche dell'Adulto
Unknown
NCT02899169 2021-09-08
APL16
First Affiliated Hospital Xi'an Jiaotong University
Phase 3 Unknown
NCT01987297 2019-08-19
Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL
Shanghai Jiao Tong University School of Medicine
Phase 4 Unknown
NCT03381781 2018-01-04
Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations
Ruijin Hospital
Phase 2 Unknown
NCT02757040 2016-04-29
Combination of Ibrutinib and As2O3 in the Treatment of CLL
Peking University People's Hospital
Phase 3 Unknown
NCT00378365 2014-04-16
Acute Promyelocytic Leukemia 2006 (APL)
Assistance Publique - Hôpitaux de Paris
Phase 3 Unknown
NCT00003885 2013-11-06
Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Leukemia, Chronic Myeloide Leukemia, Myelodysplasia, Lymphoma, or Myeloma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00196768 2007-10-23
Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic
German AML Cooperative Group
Phase 4 Unknown